The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease

被引:2
作者
Hershenson, Roy [1 ,2 ]
Nardi-Agmon, Inbar [1 ,2 ,3 ]
Leshem-Lev, Dorit [2 ,3 ]
Kornowski, Ran [1 ,2 ]
Eisen, Alon [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Cardiol, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel
关键词
Diabetes and cardiovascular disease; Endothelial progenitor cells; Cardioprotective effects of anti-diabetic medications; CARDIOVASCULAR OUTCOMES; MIGRATORY ACTIVITY; SGLT-2; INHIBITORS; PERIPHERAL-BLOOD; HEART-FAILURE; RISK-FACTORS; NUMBER; MECHANISMS; GLICLAZIDE; PROFILE;
D O I
10.1186/s12933-024-02466-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDiabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) exhibit cardioprotective benefits beyond glucose lowering, reducing the risk of major cardiovascular events (MACE) and HF hospitalizations in patients with DM and CAD. Endothelial progenitor cells (EPCs) are bone marrow-derived cells involved in vascular repair, mobilized in response to vascular injury. The number and function of circulating EPCs (cEPCs) are negatively affected by cardiovascular risk factors, including DM. This study aimed to examine the response of cEPCs to SGLT2i treatment in DM patients with stable CAD.MethodsA prospective single-center study included patients with DM and stable CAD who were started on an SGLT2i (empagliflozin). Peripheral blood samples were collected at baseline, 1 month, and 3 months to evaluate cEPC levels and function by flow cytometry, immunohistochemistry and MTT assays.ResultsEighteen patients were included in the study (median age 73, (IQR 69, 77) years, 67% male). After 1 month of treatment with empagliflozin, there was no significant change in cEPCs level or function. However, following 3 months of treatment, a significant increase was observed both in cell levels (CD34(+)/VEGFR-2(+): from 0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82), p = 0.0006; CD133(+)/VEGFR-2(+): from 0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95), p = 0.0001) and in cell function (from 0.25 CFUs (IQR 0, 0.5) at baseline, to 2 CFUs (IQR 1, 2) at 3 months, p = 0.0012).ConclusionsEmpagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
引用
收藏
页数:12
相关论文
共 102 条
[1]   SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice [J].
Adingupu, Damilola D. ;
Gopel, Sven O. ;
Gronros, Julia ;
Behrendt, Margareta ;
Sotak, Matus ;
Miliotis, Tasso ;
Dahlqvist, Ulrika ;
Gan, Li-Ming ;
Jonsson-Rylander, Ann-Cathrine .
CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
[2]   Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study [J].
Ahmed, Fahad W. ;
Rider, Rachel ;
Glanville, Michael ;
Narayanan, Kilimangalam ;
Razvi, Salman ;
Weaver, Jolanta U. .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[3]   Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial [J].
Alejandri, Luis Ricardo Balleza ;
Paez, Fernando Grover ;
Campos, Erick Gonzalez ;
Becerra, Carlos G. Ramos ;
Munoz, Ernesto German Cardona ;
Gonzalez, Sara Pascoe ;
Zavala, Maria Guadalupe Ramos ;
Roa, Africa Samantha Reynoso ;
Rico, Daniel Osmar Suarez ;
Ramirez, Alberto Beltran ;
Galindo, Jesus Jonathan Garcia ;
Mueller, David Cardona ;
Ruiz, Claudia Yanette Galan .
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2024, 11 (06)
[4]   The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair [J].
Altabas, Velimir ;
Bilos, Lora Stanka Kirigin .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
[5]   Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure [J].
Angermann, Christiane E. ;
Santos-Gallego, Carlos G. ;
Requena-Ibanez, Juan Antonio ;
Sehner, Susanne ;
Zeller, Tanja ;
Gerhardt, Louisa M. S. ;
Maack, Christoph ;
Sanz, Javier ;
Frantz, Stefan ;
Fuster, Valentin ;
Ertl, Georg ;
Badimon, Juan J. .
NATURE CARDIOVASCULAR RESEARCH, 2023, 2 (11) :1032-+
[6]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[7]   Stimulation of endothelial progenitor cells - A new putative therapeutic effect of angiotensin II receptor antagonists [J].
Bahlmann, FH ;
de Groot, K ;
Mueller, O ;
Hertel, B ;
Haller, H ;
Fliser, D .
HYPERTENSION, 2005, 45 (04) :526-529
[8]   Are Endothelial Progenitor Cells the Real Solution for Cardiovascular Diseases? Focus on Controversies and Perspectives [J].
Balistreri, Carmela R. ;
Buffa, Silvio ;
Pisano, Calogera ;
Lio, Domenico ;
Ruvolo, Giovanni ;
Mazzesi, Giuseppe .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[9]   Circulating and Tissue Resident Endothelial Progenitor Cells [J].
Basile, David P. ;
Yoder, Mervin C. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (01) :10-16
[10]   Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1 [J].
Behnammanesh, Ghazaleh ;
Durante, Giovanna L. ;
Khanna, Yash P. ;
Peyton, Kelly J. ;
Durante, William .
REDOX BIOLOGY, 2020, 32